Physician profile
John T Sweeney
NPI 1427162320
$2,257.99
in general payments reported to CMS, 2019-2025
28 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $323 · 2021: $105 · 2022: $46.61 · 2023: $72.02 · 2024: $377 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.02 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $351.95 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $345.28 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $296.90 | 2019-2025 | Viberzi, Creon, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.68 | 2019-2025 | Xifaxan |
| Fujifilm Healthcare Americas Corporation | $240.69 | 2020-2022 | |
| Boston Scientific Corporation | $98.89 | 2020-2025 | Apollo Esg Nxt System |
| Qol Medical, LLC | $91.84 | 2019-2020 | |
| Gilead Sciences, INC. | $76.34 | 2019-2025 | |
| Lilly USA, LLC | $49.59 | 2024-2025 | Omvoh |
| Ucb, INC. | $45.68 | 2019-2020 | |
| Pfizer INC. | $36.05 | 2025 | |
| Vivus LLC | $31.87 | 2025 | Pancreaze |
| Alcresta Therapeutics, INC. | $30.01 | 2024 | Relizorb |
| Madrigal Pharmaceuticals | $29.47 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $29.07 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.35 | 2025 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $23.37 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $19.59 | 2022 | |
| Alfasigma USA, INC. | $19.29 | 2020 | |
| Celgene Corporation | $18.00 | 2024 | Zeposia |
| Ardelyx, INC. | $16.88 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $16.30 | 2025 | Voquezna |
| Csl Behring | $15.25 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.99 | 2024 | Rebyota |
| Shire North American Group INC | $14.92 | 2019 | |
| Shield Therapeutics INC | $14.14 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $13.69 | 2024 | Dificid |
| Allergan, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.